MedTrace Logo

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

NCT07278362 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-02-23

No results posted yet for this study

Summary

The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on active surveillance.

Conditions

Interventions

DRUG

Testosterone cypionate

Participants will self-inject 100mg of testosterone cypionate once per week for 12 months

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Thomas Masterson, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2031-05-31
Completion
2032-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07278362 on ClinicalTrials.gov